Division of Infectious Diseases, Department of Medicine, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA.
Travel Med Infect Dis. 2005 Feb;3(1):33-8. doi: 10.1016/j.tmaid.2004.06.001.
B. hominis is a unicellular protozoan commonly identified in stool specimens of travelers who have returned from tropical countries. It has a world-wide distribution, and infection is more common in developing countries compared to industrialized nations. Clinical features of illness which have been attributed to Blastocystis include nausea, anorexia, abdominal pain, flatulence and acute or chronic diarrhea. The preferred method of diagnosis is a permanently stained smear of an unconcentrated stool specimen. The presence of B. hominis in stool specimens of symptomatic travelers should prompt clinicians to search for other unrecognized co-pathogens. Due to controversy regarding the pathogenicity of B. hominis in humans, clinicians are often faced with the dilemma of whether or not they should offer treatment for B. hominis infection in returned travelers. The most commonly used drugs for treatment include metronidazole and trimethoprim-sulfamethoxazole (TMP-SMX), when treatment is deemed necessary. Prevention in travelers should focus on food and water precautions as the organism is transmitted by the fecal-oral route.
人芽囊原虫是一种常见于从热带国家返回的旅行者粪便标本中的单细胞原生动物。它分布广泛,在发展中国家比在工业化国家更为常见。归因于芽囊原虫病的临床特征包括恶心、食欲不振、腹痛、腹胀和急性或慢性腹泻。首选的诊断方法是未浓缩粪便标本的永久性染色涂片。在有症状的旅行者的粪便标本中发现人芽囊原虫,应促使临床医生寻找其他未被识别的共病原体。由于人芽囊原虫的致病性存在争议,临床医生经常面临是否应该为返回旅行者的人芽囊原虫感染提供治疗的困境。当认为有必要治疗时,最常使用的药物包括甲硝唑和甲氧苄啶-磺胺甲恶唑(TMP-SMX)。旅行者的预防应侧重于食物和水的预防措施,因为该病原体通过粪-口途径传播。